{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T10:46:46Z","timestamp":1756810006840,"version":"3.44.0"},"reference-count":0,"publisher":"SMW Supporting Association","issue":"2122","license":[{"start":{"date-parts":[[2014,5,18]],"date-time":"2014-05-18T00:00:00Z","timestamp":1400371200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Swiss Med Wkly"],"abstract":"<jats:p>Mineralocorticoid receptor antagonists (MRA\u2019s) have been shown to be  effective in patients with HFREF while their role in patients with HFPEF  remains controversial. Despite a class \u00a0one indication in both the ESC and AHA\/ACC  heart failure guidelines in patients with HFREF MRA\u2019s remain underused, in  large part due to the fear of hyperkalaemia and renal dysfunction. While  hyperkalaemia is a potential risk of MRA\u2019s, their use when potassium and renal  function monitoring is properly carried out is minimal compared with their  benefits in appropriate patients. New nonsteriodal MRA\u2019s and new potassium  binding polymers currently under development hold the promise of further  reducing the risks of hyperkalaemia while allowing higher doses of MRA\u2019s. They  have been shown to overcome diuretic resistance and to potentially extend their  benefits to patients with acute decompensated heart failure and those with chronic  renal disease. While we await the results of studies with these new agents;  application of current guidelines recommended therapies, including MRA\u2019s hold  the best promise to further reduce cardiovascular mortality, hospitalisations  for heart failure, and therefore, health care costs in patients with heart  failure.<\/jats:p>","DOI":"10.4414\/smw.2014.13959","type":"journal-article","created":{"date-parts":[[2014,7,3]],"date-time":"2014-07-03T09:32:03Z","timestamp":1404379923000},"page":"w13959","source":"Crossref","is-referenced-by-count":3,"title":["Heart failure: the role for mineralocorticoid receptor antagonists"],"prefix":"10.57187","volume":"144","author":[{"given":"Bertram","family":"Pitt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36756","published-online":{"date-parts":[[2014,5,18]]},"container-title":["Swiss Medical Weekly"],"original-title":[],"link":[{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/1870\/2621","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/1870\/2622","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/1870\/2621","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T05:27:27Z","timestamp":1755235647000},"score":1,"resource":{"primary":{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/view\/1870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,18]]},"references-count":0,"journal-issue":{"issue":"2122","published-online":{"date-parts":[[2014,5,19]]}},"URL":"https:\/\/doi.org\/10.4414\/smw.2014.13959","relation":{},"ISSN":["1424-3997"],"issn-type":[{"type":"electronic","value":"1424-3997"}],"subject":[],"published":{"date-parts":[[2014,5,18]]}}}